Company Description

NAYA Therapeutics is pioneering the next generation of cancer therapies, aiming to unlock deeper, more durable responses in patients not responding to current standard-of-care. NAYA's pipeline harnesses the transformational potential of two synergistic modalities: astatine-211 (²¹¹At) targeted alpha therapies & NK cell engaging bifunctional antibodies, with an initial focus on hepatocellular carcinoma.